ABSTRACT
Increased mortality and morbidity occur among human immunodeficiency virus (HIV)-infected patients in whom CD4+ T-cell counts do not increase despite viral suppression with antiretroviral therapy (ART). Here we identified an underlying mechanism. Significantly elevated plasma levels of anti-CD4 immunoglobulin G (IgG) were found in HIV-positive immunologic nonresponders (ie, HIV-positive individuals with CD4+ T-cell counts of ≤350 cells/µL), compared with levels in HIV-positive immunologic responders (ie, HIV-positive individuals with CD4+ T-cell counts of ≥500 cells/µL) and healthy controls. Higher plasma level of anti-CD4 IgG correlated with blunted CD4+ T-cell recovery. Furthermore, purified anti-CD4 IgG from HIV-positive immunologic nonresponders induced natural killer (NK) cell-dependent CD4+ T-cell cytolysis and apoptosis through antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. We also found that anti-CD4 IgG-mediated ADCC exerts greater apoptosis of naive CD4+ T cells relative to memory CD4+ T cells. Consistently, increased frequencies of CD107a+ NK cells and profound decreases of naive CD4+ T cells were observed in immunologic nonresponders as compared to responders and healthy controls ex vivo. These data indicate that autoreactive anti-CD4 IgG may play an important role in blunted CD4+ T-cell reconstitution despite effective ART.
Subject(s)
Antibody-Dependent Cell Cytotoxicity , Antiretroviral Therapy, Highly Active , CD4 Antigens/immunology , HIV Infections/immunology , Immunoglobulin G/blood , Adult , Antibodies, Viral/blood , Antibodies, Viral/immunology , Antiviral Agents/blood , Antiviral Agents/therapeutic use , CD4 Lymphocyte Count , CD4-Positive T-Lymphocytes/immunology , Cross-Sectional Studies , Female , HIV , HIV Infections/blood , HIV Infections/drug therapy , Humans , Immunoglobulin G/immunology , Killer Cells, Natural/drug effects , Killer Cells, Natural/immunology , Leukocytes, Mononuclear/metabolism , Linear Models , Male , Middle Aged , Multivariate AnalysisABSTRACT
OBJECTIVES: Smoking rates are two to three times higher among people living with HIV and AIDS compared with the general population, but the prevalence of tobacco use among this population in the Charleston, SC region has not been established. To understand cigarette use, previous quit attempts, historic use of cessation therapies, and interest in cessation, a quality improvement project was implemented to survey smoking behaviors among this population. METHODS: During January-May 2010, HIV-infected patients arriving to the Medical University of South Carolina Infectious Diseases clinic were asked to complete a survey. Clinical and sociodemographic data were collected and analyzed using χ(2), and one-way analysis of variance models. RESULTS: Of unduplicated clinic encounters, 514 (75%) of patients completed the smoking survey. Less than half of responders were current (205, 40%) or former (42, 8%) smokers, with smoking prevalence higher for Caucasian males. Among current smokers, 170 (85%) reported having ever attempted to quit with the majority making a quit attempt without medication therapy (143, 83%). Nearly half of all current smokers (97, 49%) reported an active interest in speaking with a physician about quitting. Smoking status did not have meaningful relationships with HIV biomarkers, even when stratified by race and gender. CONCLUSIONS: This study supports that high rates of smoking exist in the south among people living with HIV and AIDS and demonstrated a need for smoking cessation interventions among these patients. These data have potentiated the hiring of a clinical pharmacist to aid in implementation of smoking cessation therapies in a more systematic and formal way.
Subject(s)
HIV Infections/epidemiology , Smoking/epidemiology , Black or African American/statistics & numerical data , CD4 Lymphocyte Count , Female , Humans , Male , Middle Aged , Outpatient Clinics, Hospital , Sex Distribution , Smoking Cessation , South Carolina/epidemiology , Viral Load , White People/statistics & numerical dataABSTRACT
UNLABELLED: The effects of heightened microbial translocation on B cells during HIV infection are unknown. We examined the in vitro effects of HIV and lipopolysaccharide (LPS) on apoptosis of CD27+ IgD- memory B (mB) cells from healthy controls. In vivo analysis was conducted on a cohort of 82 HIV+ donors and 60 healthy controls. In vitro exposure of peripheral blood mononuclear cells (PBMCs) to LPS and HIV led to mB cell death via the Fas/Fas ligand (FasL) pathway. Plasmacytoid dendritic cells (pDCs) produced FasL in response to HIV via binding to CD4 and chemokine coreceptors. HIV and LPS increased Fas expression on mB cells in PBMCs, which was dependent on the presence of pDCs and monocytes. Furthermore, mB cells purified from PBMCs and pretreated with both HIV and LPS were more sensitive to apoptosis when cocultured with HIV-treated pDCs. Blocking the interferon receptor (IFNR) prevented HIV-stimulated FasL production in pDCs, HIV-plus-LPS-induced Fas expression, and apoptosis of mB cells. In vivo or ex vivo, HIV+ donors have higher levels of plasma LPS, Fas expression on mB cells, and mB cell apoptosis than controls. Correspondingly, in HIV+ donors, but not in controls, a positive correlation was found between plasma FasL and HIV RNA levels and between Fas expression on mB cells and plasma LPS levels. This work reveals a novel mechanism of mB cell apoptosis mediated by LPS and HIV through the Fas/FasL pathway, with key involvement of pDCs and type I IFN, suggesting a role for microbial translocation in HIV pathogenesis. IMPORTANCE: This study demonstrates that lipopolysaccharide (LPS) and type I interferon (IFN) play an important role in memory B cell apoptosis in HIV infection. It reveals a previously unrecognized role of microbial translocation in HIV pathogenesis.
Subject(s)
Apoptosis/immunology , B-Lymphocytes/immunology , HIV Infections/immunology , HIV-1/immunology , Lipopolysaccharides/immunology , B-Lymphocytes/drug effects , B-Lymphocytes/pathology , Bacteria/chemistry , Bacteria/immunology , Bacterial Translocation , Cell Separation , Cells, Cultured , Dendritic Cells/drug effects , Dendritic Cells/immunology , Dendritic Cells/pathology , Fas Ligand Protein/genetics , Fas Ligand Protein/immunology , Gene Expression Regulation , HIV Infections/genetics , HIV Infections/microbiology , HIV Infections/pathology , Host-Pathogen Interactions , Humans , Immunoglobulin D/genetics , Immunologic Memory , Interferon Type I/genetics , Interferon Type I/immunology , Lipopolysaccharides/pharmacology , Monocytes/drug effects , Monocytes/immunology , Monocytes/pathology , Signal Transduction , Tumor Necrosis Factor Receptor Superfamily, Member 7/genetics , Tumor Necrosis Factor Receptor Superfamily, Member 7/immunology , fas Receptor/genetics , fas Receptor/immunologyABSTRACT
Herpes simplex virus (HSV) infections are highly prevalent and may have devastating consequences if transmitted to newborns. The highest risk of transmission is when the mother has primary HSV infection (rather than recurrence of chronic infection) late in pregnancy. Clinicians should obtain a careful history, performing serologic testing and counseling as appropriate. Delayed diagnosis of neonatal HSV is associated with high mortality. Even with adequate treatment, permanent sequelae, such as cerebral palsy and developmental delay, may occur. Clinicians should develop prudent strategies to avoid primary HSV acquisition during pregnancy, and provide prophylaxis or treatment when indicated.
Subject(s)
Herpes Simplex/prevention & control , Infectious Disease Transmission, Vertical/prevention & control , Pregnancy Complications, Infectious/therapy , Antiviral Agents/therapeutic use , Breast Feeding , Female , Fetal Membranes, Premature Rupture , Herpes Genitalis/diagnosis , Herpes Genitalis/transmission , Herpes Simplex/drug therapy , Herpes Simplex/transmission , Humans , Infant, Newborn , Pregnancy , Premature Birth/prevention & control , SimplexvirusABSTRACT
BACKGROUND: It is unknown whether sex and race influence clinical outcomes following primary human immunodeficiency virus type 1 (HIV-1) infection. METHODS: Data were evaluated from an observational, multicenter, primarily North American cohort of HIV-1 seroconverters. RESULTS: Of 2277 seroconverters, 5.4% were women. At enrollment, women averaged .40 log10 fewer copies/mL of HIV-1 RNA (P < .001) and 66 more CD4(+) T cells/µL (P = .006) than men, controlling for age and race. Antiretroviral therapy (ART) was less likely to be initiated at any time point by nonwhite women and men compared to white men (P < .005), and by individuals from the southern United States compared to others (P = .047). Sex and race did not affect responses to ART after 6 months (P > .73). Women were 2.17-fold more likely than men to experience >1 HIV/AIDS-related event (P < .001). Nonwhite women were most likely to experience an HIV/AIDS-related event compared to all others (P = .035), after adjusting for intravenous drug use and ART. Eight years after diagnosis, >1 HIV/AIDS-related event had occurred in 78% of nonwhites and 37% of whites from the southern United States, and 24% of whites and 17% of nonwhites from other regions (P < .001). CONCLUSIONS: Despite more favorable clinical parameters initially, female HIV-1-seroconverters had worse outcomes than did male seroconverters. Elevated morbidity was associated with being nonwhite and residing in the southern United States.
Subject(s)
Disease Transmission, Infectious , HIV Infections/epidemiology , HIV-1/isolation & purification , Adult , Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active , CD4 Lymphocyte Count , Cohort Studies , Female , Geography , HIV Infections/drug therapy , HIV Infections/pathology , HIV Infections/virology , Humans , Male , North America/epidemiology , RNA, Viral/blood , Racial Groups , Risk Factors , Sex Factors , Treatment OutcomeABSTRACT
The precise identification of the HIV-1 envelope glycoprotein (Env) responsible for productive clinical infection could be instrumental in elucidating the molecular basis of HIV-1 transmission and in designing effective vaccines. Here, we developed a mathematical model of random viral evolution and, together with phylogenetic tree construction, used it to analyze 3,449 complete env sequences derived by single genome amplification from 102 subjects with acute HIV-1 (clade B) infection. Viral env genes evolving from individual transmitted or founder viruses generally exhibited a Poisson distribution of mutations and star-like phylogeny, which coalesced to an inferred consensus sequence at or near the estimated time of virus transmission. Overall, 78 of 102 subjects had evidence of productive clinical infection by a single virus, and 24 others had evidence of productive clinical infection by a minimum of two to five viruses. Phenotypic analysis of transmitted or early founder Envs revealed a consistent pattern of CCR5 dependence, masking of coreceptor binding regions, and equivalent or modestly enhanced resistance to the fusion inhibitor T1249 and broadly neutralizing antibodies compared with Envs from chronically infected subjects. Low multiplicity infection and limited viral evolution preceding peak viremia suggest a finite window of potential vulnerability of HIV-1 to vaccine-elicited immune responses, although phenotypic properties of transmitted Envs pose a formidable defense.
Subject(s)
Disease Transmission, Infectious , Evolution, Molecular , HIV Infections/transmission , HIV Infections/virology , HIV-1/genetics , env Gene Products, Human Immunodeficiency Virus/genetics , AIDS Vaccines/immunology , Base Sequence , Genetic Variation , HIV Antibodies/immunology , HIV Infections/immunology , HIV-1/isolation & purification , HIV-1/physiology , Humans , Models, Biological , Molecular Sequence Data , Mutation , Phylogeny , RNA, Viral/blood , RNA, Viral/genetics , Receptors, CCR5/metabolism , Sequence Analysis, RNA , env Gene Products, Human Immunodeficiency Virus/immunologyABSTRACT
Acute human immunodeficiency virus type 1 (HIV-1) infection is characterized by high levels of immune activation. Immunomodulation with cyclosporine combined with antiretroviral therapy (ART) in the setting of acute and early HIV-1 infection has been reported to result in enhanced immune reconstitution. Fifty-four individuals with acute and early infection were randomized to receive ART with 4 weeks of cyclosporine versus ART alone. In 48 subjects who completed the study, there were no significant differences between treatment arms in levels of proviral DNA or CD4(+) T cell counts. Adjunctive therapy with cyclosporine in this setting does not provide apparent virologic or immunologic benefit.
Subject(s)
Anti-HIV Agents/therapeutic use , Cyclosporine/therapeutic use , HIV Infections/drug therapy , Immunosuppressive Agents/therapeutic use , Adult , Anti-HIV Agents/administration & dosage , Antiretroviral Therapy, Highly Active , CD4 Lymphocyte Count , Cyclosporine/administration & dosage , Drug Therapy, Combination , Female , HIV-1/drug effects , Humans , Immunosuppressive Agents/administration & dosage , Male , Viral Load/drug effectsABSTRACT
We describe a mathematical model and Monte Carlo (MC) simulation of viral evolution during acute infection. We consider both synchronous and asynchronous processes of viral infection of new target cells. The model enables an assessment of the expected sequence diversity in new HIV-1 infections originating from a single transmitted viral strain, estimation of the most recent common ancestor (MRCA) of the transmitted viral lineage, and estimation of the time to coalesce back to the MRCA. We also calculate the probability of the MRCA being the transmitted virus or an evolved variant. Excluding insertions and deletions, we assume HIV-1 evolves by base substitution without selection pressure during the earliest phase of HIV-1 infection prior to the immune response. Unlike phylogenetic methods that follow a lineage backwards to coalescence, we compare the observed data to a model of the diversification of a viral population forward in time. To illustrate the application of these methods, we provide detailed comparisons of the model and simulations results to 306 envelope sequences obtained from eight newly infected subjects at a single time point. The data from 68 patients were in good agreement with model predictions, and hence compatible with a single-strain infection evolving under no selection pressure. The diversity of the samples from the other two patients was too great to be explained by the model, suggesting multiple HIV-1-strains were transmitted. The model can also be applied to longitudinal patient data to estimate within-host viral evolutionary parameters.
Subject(s)
Evolution, Molecular , HIV Infections/virology , HIV-1/genetics , Models, Genetic , Acute Disease , Female , Genetic Variation , Humans , Male , Monte Carlo Method , PhylogenyABSTRACT
BACKGROUND: Interleukin 2 (IL-2) administration increases CD4 counts in persons with higher counts. This study investigated persons with moderately advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy (HAART). METHODS: Two hundred four patients with CD4 T-cell counts from 50/microL to 350/microL who were treatment naive or had been treated only with reverse transcriptase inhibitors began a specified protease inhibitor HAART regimen. Virologic responders (< or =5000 copies/mL) at 12 weeks were randomized to open-label continuous-infusion IL-2 (IV IL-2), subcutaneous IL-2 (SC IL-2), or HAART alone. Thirty were not randomized and 15 enrolled in a substudy, leaving 159 for analysis. Subjects continued HAART alone for 72 weeks (n = 52) or with IV IL-2 (n = 53) or SC IL-2 (n = 54) for 5 days every 8 weeks. The IV IL-2 subjects could switch to SC IL-2 if their CD4 T-cell count increased by 100/microL or by 25%. RESULTS: Patients receiving IV or SC IL-2 had greater increases in CD4 cell counts. At week 84, median increases were 459/microL, 312/microL, and 102/microL. Increases of greater than 50% at week 60 (primary end point) were achieved in 39 patients (81%) and 32 (67%) in the IV and SC IL-2 arms, respectively, compared with 13 (29%) in the HAART arm (P<.001 for both). Treatment with IL-2 did not increase plasma human immunodeficiency virus RNA levels. There were fewer new AIDS-defining events in the IV (P = .006) and SC (P = .03) IL-2 groups than in the HAART group (0, 1, and 7, respectively). Drug-related adverse events were more frequent with IL-2 treatment. CONCLUSION: Addition of IL-2 to HAART can significantly expand CD4 T-cell counts in moderately advanced human immunodeficiency virus infection, without loss of virologic control.
Subject(s)
Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active , HIV Infections/drug therapy , Interleukin-2/therapeutic use , Adolescent , Adult , Aged , CD4 Lymphocyte Count , Drug Administration Schedule , Female , HIV Infections/mortality , HIV Infections/virology , Humans , Infusions, Intravenous , Injections, Subcutaneous , Male , Middle Aged , RNA, Viral/blood , Time FactorsABSTRACT
It is well established that retention in high-quality care and regular visits with an HIV/AIDS provider improve outcomes for people living with HIV/AIDS (PLWHA). However, nationally and regionally in South Carolina, retention rates remain low. We piloted an outreach program focused on characterizing out of care (OOC) patients to identify PLWHA who were lost to care and attempt reengagement through phone call, letter, and home visit interventions. Primary outcomes were reengagement, defined as attendance to a clinic appointment, and retention in care, defined by the Health Resources and Services Administration (HRSA) definition (two visits at least 90 days apart in 2015). There were 1242 adult clinic patients in 2014. A total of 233 patients were included in the OOC cohort, according to the inclusion criteria. Of these 233, the outreach coordinator found that a majority of patients, 119 (51%), were lost to care. Reengagement was seen in 52 (44%) patients lost to care, and among those who reengaged, 26 (50%) were retained in care in 2015. This report represents one of few interventions that target reengagement for patients who are lost to care. The use of an outreach coordinator was successful in reengaging and retaining patients in care. It represents an uncomplicated intervention, functional within the current clinic design and available funding structure of the Ryan White grant. Poor engagement and retention in care continue to be significant problems among PLWHA with resultant poor clinical outcomes. Continued focus on new interventions to improve retention in care is necessary to improve clinical outcomes.
Subject(s)
Ambulatory Care Facilities/organization & administration , Community-Institutional Relations , HIV Infections/drug therapy , Health Services Accessibility , Patient Acceptance of Health Care , Patient Dropouts/psychology , Adult , Appointments and Schedules , Female , HIV Infections/psychology , Healthcare Disparities , Humans , Male , Patient Compliance , Pilot Projects , Program Evaluation , South Carolina , Viral LoadABSTRACT
Enfuvirtide (ENF) is the first of a new class of antiretrovirals (ARVs) known as the HIV fusion inhibitors. Two phase III studies of ENF, TORO 1 and TORO 2, demonstrated that ENF given in combination with optimized background (OB) therapy significantly improved virological response, increased the time to virological failure, and increased CD4-cell count compared with OB alone among highly treatment-experienced patients. The present study investigated the long-term clinical outcomes, costs, and cost-effectiveness of ENF. Outcomes, costs, and cost-effectiveness were estimated using a Markov model. Viral suppression and immune reconstitution were determined from the outcomes of the clinical trials. Time to immunological failure, time to AIDS-defining event (ADE), and time to death were estimated based on published mathematical models of disease progression. Costs were based on published estimates of the use and costs of ARVs, cost of managing ADEs, and cost of laboratory and other outpatient services. Cost-effectiveness was calculated as the incremental cost per year of life gained, adjusted for quality of life. The combined effects of an increase in CD4 count and delayed time to virological and immunological failure with ENF + OB were predicted to produce a mean life expectancy of 7.4 years from initiation of therapy, which was 1.8 years (1.5 quality-adjusted lifeyears [QALYs]) greater than the life expectancy associated with OB alone. The incremental cost-effectiveness of ENF + OB was estimated to be Dollars 24,604 per QALY. ENF is projected to increase time to immunological failure, delay onset of new AIDS-defining events, and increase life expectancy by more than 1.5 years among treatment-experienced HIV-infected patients. The cost-effectiveness of ENF is comparable to many existing treatment and prevention management strategies for HIV.
Subject(s)
HIV Envelope Protein gp41/economics , HIV Envelope Protein gp41/therapeutic use , HIV Fusion Inhibitors/economics , HIV Fusion Inhibitors/therapeutic use , HIV Infections/drug therapy , HIV Infections/economics , Peptide Fragments/economics , Peptide Fragments/therapeutic use , CD4 Lymphocyte Count , Computer Simulation , Cost-Benefit Analysis , Disease Progression , Drug Therapy, Combination , Enfuvirtide , HIV Infections/mortality , Humans , Markov Chains , Models, Biological , Quality of Life , Survival Analysis , Treatment Failure , Treatment Outcome , United States/epidemiologyABSTRACT
BACKGROUND: Actinomyces, particularly Actinomyces israelii, may cause indolent, persistent infections or represent normal mucosal flora, leading to management dilemmas. MATERIALS AND METHODS: Prompted by a refractory Actinomyces meyeri infection complicating AIDS, clinical data for all Actinomyces isolates at our hospital laboratory since 1998 were analyzed. RESULTS: A total of 140 cases had a positive result for Actinomyces cultures. Of 130 cases with adequate follow-up, 36 (28%) cases had end-organ or disseminated disease treated with prolonged antibiotics or surgery or both (Group 1). A. meyeri was more common than A. israelii (33% versus 8%; P < 0.05) in Group 1, particularly thoracic infections. Another 56 (43%) cases were considered local pathogens, treated with drainage only or short-course antibiotics (Group 2). Another 38 (29%) cases were deemed commensals (Group 3). Immunosuppression was less frequent in Group 1 versus Group 2 or 3 (P = 0.05) and human immunodeficiency virus or AIDS was uncommon. Foreign bodies or devices (Group 1 versus Group 2 or 3, P = 0.003) and alcoholism (Group 1 versus Group 2 or 3; P = 0.03) were associated with actinomycosis. Isolates from the central nervous system and musculoskeletal sites were more often treated as definitive disease; skin, abdominal or pelvic or single blood culture isolates were more likely commensals (all P < 0.05). Disease progression or recurrence did not occur in Groups 2 and 3, whereas Group 1 had complex and variable courses, including 2 deaths. CONCLUSIONS: In the absence of disseminated or end-organ disease, avoiding prolonged therapy for Actinomyces isolates was not associated with adverse outcomes. Alcoholism or foreign bodies were associated with actinomycosis. A. meyeri may be a more common cause of actinomycosis than previously recognized.
Subject(s)
Actinomyces/isolation & purification , Actinomycosis/epidemiology , Actinomycosis/microbiology , Acquired Immunodeficiency Syndrome/complications , Acquired Immunodeficiency Syndrome/epidemiology , Actinomycosis/complications , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Female , Humans , Infant , Male , Middle Aged , Organ Transplantation/adverse effects , Retrospective Studies , Risk Factors , South Carolina/epidemiology , Young AdultABSTRACT
BACKGROUND: There is increasing recognition of the role of B cell dysfunction in HIV pathogenesis, but little is known about how these perturbations may influence responses to vaccinations. METHODS: Healthy controls (n=16) and antiretroviral therapy (ART)-treated aviremic HIV-infected subjects (n=26) receiving standard-of-care annual influenza vaccinations were enrolled in the present study. Total bacterial 16S rDNA levels were assessed by quantitative polymerase chain reactions in plasma. Serologic responses were characterized by ELISA, hemagglutination inhibition assay (HI), and microneutralization, and cell-mediated responses were assessed by ELISPOT (antigen-specific IgG+ antibody-secreting cells (ASCs)) and flow cytometry at pre-vaccination (D0), day 7-10 (D7) and day 14-21 (D14) post-vaccination. RESULTS: Decreased peripheral CD4+ T cell absolute counts and increased frequencies of cycling and apoptotic B cells were found at baseline in HIV-infected subjects relative to healthy controls. In healthy controls, post-vaccination neutralizing activities were related to the frequencies of vaccine-mediated apoptosis and cycling of B cells, but not to CD4+ T cell counts. In patients, both baseline and post-vaccination neutralizing activities were directly correlated with plasma level of bacterial 16S rDNA. However, overall vaccine responses including antibody titers and fold changes were comparable or greater in HIV-infected subjects relative to healthy controls. CONCLUSION: B cell function correlates with measures of recall humoral immunity in response to seasonal influenza vaccination in healthy controls but not in ART-treated patients.
Subject(s)
B-Lymphocytes/immunology , HIV Infections/immunology , Influenza Vaccines/immunology , Lymphocyte Activation , Adult , Anti-Retroviral Agents/therapeutic use , Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Apoptosis , Bacterial Translocation , CD4 Lymphocyte Count , Case-Control Studies , Female , HIV Infections/drug therapy , Hemagglutination Inhibition Tests , Humans , Immunity, Cellular , Immunity, Humoral , Influenza A Virus, H1N1 Subtype , Influenza A Virus, H3N2 Subtype , Influenza Vaccines/administration & dosage , Influenza, Human/prevention & control , Male , Middle Aged , Neutralization Tests , RNA, Bacterial/isolation & purification , RNA, Ribosomal, 16S/isolation & purificationABSTRACT
OBJECTIVE: To understand the mechanisms underlying the differential targeting of T-cell responses during HIV-1 disease progression. DESIGN: We performed a cross-sectional analysis of HIV specific CD8 T-cell responses in peripheral blood mononuclear cells (PBMC) obtained from 21 subjects with well characterized acute or early infection and 88 subjects with chronic HIV-1 infection. We also performed a longitudinal analysis of T-cell responses in five early infected subjects one of whom was studied extensively over a 4-year-period. METHODS: PBMC were stimulated with pools of peptides encompassing all of the HIV-1 proteins in an interferon-gamma ELISpot assay. A mean entropy score was calculated for each peptide in the HIV-1 genome. RESULTS: The early infected group preferentially targeted variable peptides with higher entropy while responses towards more conserved peptides with lower entropy predominated in the group with chronic infection. In five early infected subjects followed longitudinally, responses to variable proteins declined while those to conserved proteins increased over time. In the subject who was followed for 4 years, epitopes in Vif and Nef were targeted early and escape occurred in three of these four epitopes. During the chronic phase of his infection, the early responses waned with an associated increase in breadth of T-cell responses mainly to Gag and Pol epitopes. CONCLUSION: Taken together, these data demonstrate that HIV-specific CD8 T cells are directed preferentially to the variable peptides in early infection but diminish in frequency during chronic disease, in large part due to cytotoxic T lymphocyte escape.
Subject(s)
CD8-Positive T-Lymphocytes/immunology , HIV Infections/immunology , HIV-1 , Viral Proteins/immunology , Acute Disease , Adolescent , Adult , Aged , Amino Acid Sequence , Cells, Cultured , Chronic Disease , Cross-Sectional Studies , Entropy , Epitopes, T-Lymphocyte/genetics , Epitopes, T-Lymphocyte/immunology , Humans , Interferon-gamma/biosynthesis , Longitudinal Studies , Lymphocyte Activation/immunology , Middle Aged , Molecular Sequence Data , Peptide Fragments/immunologyABSTRACT
Streptococcus pneumoniae (pneumococcus) remains one of the most commonly identified causes of bacterial infection in the general population, and the risk is 30-100 fold higher in HIV-infected individuals. Both innate and adaptive host immune responses to pneumococcal infection are important against pathogen invasion. Pneumococcal-specific IgA antibody (Ab) is key to control infection at the mucosal sites. Ab responses against pneumococcal infection by B cells can be generated through T cell-dependent or T cell-independent pathways. Depletion of CD4+ T cells is a hallmark of immunodeficiency in HIV infection and this defect also contributes to B cell dysfunction, which predisposes to infections such as the pneumococcus. Two pneumococcal vaccines have been demonstrated to have potential benefits for HIV-infected patients. One is a T cell dependent 13-valent pneumococcal conjugate vaccine (PCV13); the other is a T cell independent 23-valent pneumococcal polysaccharide vaccine (PPV23). However, many questions remain unknown regarding these two vaccines in the clinical setting in HIV disease. Here we review the latest research regarding B cell immune responses against pneumococcal antigens, whether derived from potentially invading pathogens or vaccinations, in the setting of HIV-1 infection.
Subject(s)
B-Lymphocytes/immunology , HIV Infections/immunology , Immunity, Humoral , Pneumococcal Infections/immunology , Streptococcus pneumoniae/immunology , HIV Infections/virology , HIV-1/isolation & purification , Humans , Pneumococcal Vaccines/immunologyABSTRACT
The SINGLE study was a randomized, double-blind, noninferiority study that evaluated the safety and efficacy of 50 mg dolutegravir + abacavir/lamivudine versus efavirenz/tenofovir/emtricitabine in 833 ART-naive HIV-1 + participants. Of 833 randomized participants, 71% in the dolutegravir + abacavir/lamivudine arm and 63% in the efavirenz/tenofovir/emtricitabine arm maintained viral loads of <50 copies per milliliter through W144 (P = 0.01). Superior efficacy was primarily driven by fewer discontinuations due to adverse events in the dolutegravir + abacavir/lamivudine arm [dolutegravir + abacavir/lamivudine arm, 16 (4%); efavirenz/tenofovir/emtricitabine arm, 58 (14%)] through W144 [corrected]. No treatment-emergent integrase or nucleoside resistance was observed in dolutegravir + abacavir/lamivudine recipients through W144.
Subject(s)
Dideoxynucleosides/administration & dosage , Dideoxynucleosides/therapeutic use , HIV Infections/drug therapy , HIV-1 , Heterocyclic Compounds, 3-Ring/administration & dosage , Heterocyclic Compounds, 3-Ring/therapeutic use , Lamivudine/administration & dosage , Lamivudine/therapeutic use , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/therapeutic use , Double-Blind Method , Drug Administration Schedule , Drug Combinations , Drug Therapy, Combination , Humans , Oxazines , Piperazines , PyridonesABSTRACT
OBJECTIVES: The primary objective was to determine the long-term safety of the subcutaneous self-administration of enfuvirtide. Secondary objectives included the determination of enfuvirtide pharmacokinetics and antiviral activity and the immunological response to the enfuvirtide-containing regimen. METHODS: A multicenter 48-week uncontrolled open-label rollover study was conducted on 71 HIV-infected adults recruited from previous enfuvirtide clinical trials. Patients with extensive previous use of protease and reverse transcriptase inhibitors received a twice-daily dose of 50 mg enfuvirtide subcutaneously (45 mg deliverable) combined with two or more antiretroviral drugs selected for each individual, guided by resistance testing and previous treatment history. RESULTS: The mean baseline plasma HIV-RNA level was 4.81 log(10) copies/ml and the mean CD4 cell count was 134.8 cells/microl. The majority (86.9%) of treatment-emergent adverse events were grade 2 or less in severity. Injection site reactions were common, but no patients discontinued treatment. A mean HIV-RNA change of -1.33 log(10) was achieved within 14 days of treatment initiation. At week 48, approximately one-third of all patients in the intent-to-treat population maintained significant suppression of plasma HIV RNA, with either less than 400 copies/ml or more than a 1.0 log(10) decline from baseline. The mean gain in absolute CD4 cell counts at 48 weeks was 84.9 cells/microl. Trough plasma concentrations of enfuvirtide were consistently higher than target concentrations. CONCLUSION: Self-administration of enfuvirtide is not associated with unexpected toxicities for up to one year, and combined with oral antiretroviral drugs was associated with a significant decrease in HIV RNA and an increase in CD4 cell counts.
Subject(s)
Anti-HIV Agents/adverse effects , HIV Envelope Protein gp41/adverse effects , HIV Infections/drug therapy , HIV-1 , Peptide Fragments/adverse effects , Adult , Aged , Anti-HIV Agents/blood , Anti-HIV Agents/therapeutic use , CD4 Lymphocyte Count , Drug Therapy, Combination , Enfuvirtide , Female , HIV Envelope Protein gp41/blood , HIV Envelope Protein gp41/therapeutic use , HIV Infections/blood , HIV Infections/immunology , HIV Infections/virology , HIV-1/isolation & purification , Humans , Male , Middle Aged , Peptide Fragments/blood , Peptide Fragments/therapeutic use , RNA, Viral/bloodABSTRACT
Enfuvirtide (T-20) is a novel antiretroviral agent that blocks HIV-1 cell fusion. A 28-day randomized dose-comparison study was conducted to determine the safety, pharmacokinetics, and antiviral activity of enfuvirtide in 78 HIV-infected adults, most with extensive treatment experience. Patients received enfuvirtide, added to a failing regimen, either by continuous subcutaneous infusion (CSI: 12.5, 25, 50 or 100 mg/day) or by subcutaneous (SC) injection (50 or 100 mg twice daily). Dose-related decreases in viral load were observed, with a maximum mean reduction from baseline of 1.6 log(10) copies/ml (p< 0.001) seen in the 100 mg bid SC group. Most responses diminished by 28 days. Plasma pharmacokinetics and antiviral responses were more consistent for SC injection than for CSI because of technical difficulties experienced with CSI. Injection site reactions were common but generally mild. These results indicate that enfuvirtide is a promising new therapeutic agent for HIV-infected patients, including those with prior antiretroviral treatment.
Subject(s)
Acquired Immunodeficiency Syndrome/drug therapy , Anti-HIV Agents/adverse effects , HIV Envelope Protein gp41/adverse effects , Peptide Fragments/adverse effects , Acquired Immunodeficiency Syndrome/immunology , Acquired Immunodeficiency Syndrome/virology , Adult , CD4 Lymphocyte Count , Dose-Response Relationship, Drug , Enfuvirtide , HIV Envelope Protein gp41/therapeutic use , HIV-1/genetics , Humans , Injections, Subcutaneous , Middle Aged , Peptide Fragments/pharmacokinetics , Peptide Fragments/therapeutic use , RNA, Viral/bloodABSTRACT
Despite the overall success of antiretroviral medications in reducing the morbidity and mortality associated with HIV infection, many patients on treatment suffer progressive disease due to intolerance or the development of resistant viral strains. Consequently, considerable research focuses on the development of new classes of antiretroviral agents with mechanisms of action different to the current classes. Enfuvirtide (T-20, pentafuside, Fuzeon), the first drug of a new class of antiretroviral medications known as fusion inhibitors, blocks the fusion of the virus particle with the host target cell. The viral entry process begins with the attachment of viral surface glycoprotein gp120 to the host cell CD4 and chemokine receptor sites. Viral gp41 then undergoes a conformational change enabling fusion of both membranes, a critical step in the viral life cycle. Enfuvirtide is a synthetic peptide that binds to gp41, preventing the conformational change required for membrane fusion. Based on potent in vitro activity, a Phase I clinical trial of intravenous enfuvirtide was conducted that demonstrated a substantial decline in HIV plasma viral load in the highest dose group and no serious adverse effects. Phase II trials evaluated regimens of both continuous subcutaneous infusions and intermittent subcutaneous injections. Intermittent injections were pharmacokinetically superior to continuous infusions and were associated with fewer administration difficulties. For some subjects who added enfuvirtide monotherapy to an already failing regimen, the beneficial effect on viral load reduction appeared short-lived, suggesting the development of resistance. Two large randomised clinical trials comparing "optimised background" (best available, individualised regimens based on patient history and resistance assays) versus optimised background plus enfuvirtide have recently shown a significant virological advantage (approximately 1 log(10) difference from controls) at 24 weeks. In all trials to date, very few significant adverse effects have been seen--minor injection site reactions are frequent, but rarely treatment limiting. Based on these studies, enfuvirtide will likely play a significant role in the treatment of patients with limited treatment options.